CLINICAL TRIALS PROFILE FOR GADOXETATE DISODIUM
✉ Email this page to a colleague
All Clinical Trials for GADOXETATE DISODIUM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01867424 ↗ | Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 2013-05-14 | Background: - Prostate cancer is the most common cancer type among men. Some prostate cancers respond to hormonal therapy. However, some cell characteristics of other prostate cancers cause it not to respond as well to these therapies. Researchers want to see if gadoxetate, a contrast agent used to help identify damaged liver tissue, can help tell these types of prostate cancer apart. It may be able to identify if a man has a type of prostate cancer for which hormone therapy may not work as well. Objectives: - To see if gadoxetate can help identify different types of prostate cancers during imaging studies. Eligibility: - Men at least 18 years of age who have prostate cancer. Participants will be having surgery to either remove the prostate or take tumor tissue samples. Design: - Participants will be screened with a physical exam and medical history. Blood samples will be collected. - Participants will have a magnetic resonance imaging (MRI) scan of the lower torso. They will receive gadoxetate during the MRI scan. - Participants who have surgery will have a sample of their tumor cells collected. Those who have a biopsy will provide cells from this biopsy for study. - Treatment will not be provided as part of this study. |
| NCT02156739 ↗ | Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions | Recruiting | National Cancer Institute (NCI) | N/A | 2014-10-13 | This clinical trial studies contrast-enhanced magnetic resonance imaging (MRI) in detecting nonmalignant and malignant liver lesions. Diagnostic procedures, such as MRI, may help find and diagnose nonmalignant and malignant liver lesions. Contrast agents, such as gadoxetate disodium and gadobutrol, may help doctors to see MRI images more clearly. |
| NCT02156739 ↗ | Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions | Recruiting | M.D. Anderson Cancer Center | N/A | 2014-10-13 | This clinical trial studies contrast-enhanced magnetic resonance imaging (MRI) in detecting nonmalignant and malignant liver lesions. Diagnostic procedures, such as MRI, may help find and diagnose nonmalignant and malignant liver lesions. Contrast agents, such as gadoxetate disodium and gadobutrol, may help doctors to see MRI images more clearly. |
| NCT02226666 ↗ | Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration | Completed | University of Michigan | 2013-08-01 | The purpose of this study is to prospectively compare the physiologic response of patients who receive either intravenous gadoxetic acid (Eovist) or intravenous gadobenate dimeglumine (MultiHance). | |
| NCT02431598 ↗ | Eovist vs. Dotarem Healthy Volunteer MRI | Completed | University of California, San Diego | Phase 4 | 2015-06-01 | The purpose of this study is to evaluate changes in volunteer breath-holding capacity in response to gadoxetate disodium (Eovist) administration, compared with saline, and gadoterate dimeglumine (Dotarem). Healthy volunteers will be recruited from three study sites. These subjects will be given three, blinded, randomized injections while undergoing an MRI of their liver and holding their breath. During the scan, the subjects' oxygen saturation and heart rate will be closely monitored. Following the scan, the subjects will complete a questionnaire regarding the breath hold. |
| NCT02431598 ↗ | Eovist vs. Dotarem Healthy Volunteer MRI | Completed | University of Wisconsin, Madison | Phase 4 | 2015-06-01 | The purpose of this study is to evaluate changes in volunteer breath-holding capacity in response to gadoxetate disodium (Eovist) administration, compared with saline, and gadoterate dimeglumine (Dotarem). Healthy volunteers will be recruited from three study sites. These subjects will be given three, blinded, randomized injections while undergoing an MRI of their liver and holding their breath. During the scan, the subjects' oxygen saturation and heart rate will be closely monitored. Following the scan, the subjects will complete a questionnaire regarding the breath hold. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GADOXETATE DISODIUM
Condition Name
Clinical Trial Locations for GADOXETATE DISODIUM
Trials by Country
Clinical Trial Progress for GADOXETATE DISODIUM
Clinical Trial Phase
Clinical Trial Sponsors for GADOXETATE DISODIUM
Sponsor Name
